Kusajili – Clinical trials directory

Result of your search per sponsor: Berna Biotech AG (Switzerland)

Berna Biotech AG (Switzerland) Update Il y a 4 ans

A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal® with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month schedule Not provided at time of registration

Country Chile
organs None
Specialty None

Closed trial

More information